News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Tranzyme Pharma and Norgine Complete Enrollment in ULISES 008, the Second of Two Phase 3 Pivotal Trials of Ulimorelin


2/28/2012 9:35:14 AM

RESEARCH TRIANGLE PARK, N.C. and AMSTERDAM, the Netherlands, Feb. 27, 2012 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM) and Norgine B.V. today announced completion of patient enrollment in ULISES 008, the second of two Phase 3 pivotal trials of ulimorelin for the acceleration of gastrointestinal (GI) recovery in patients undergoing abdominal surgery. Enrollment in ULISES 007, the first Phase 3 pivotal trial, was completed in December 2011. There are an estimated 1 million patients in the U.S. at high risk each year for delayed GI recovery after surgery, including approximately 340,000 bowel resection surgeries.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES